Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Bliss GVS Pharma Limited is a leading player in the specialty and generic pharmaceuticals sector, primarily focusing on the production of high-quality formulations and drug delivery systems. The company has a strong presence in emerging markets, particularly in India and Southeast Asia, and benefits from its robust R&D capabilities and a diverse product portfolio that includes over 200 formulations.
Bliss GVS Pharma generates revenue through the production and sale of generic and specialty drugs, leveraging its strong R&D capabilities to develop cost-effective formulations. The company enjoys pricing power due to its established brand reputation and regulatory compliance, which enhances its competitive advantage in the market.
Regulatory approvals for new drug formulations
Market expansion in Southeast Asia
Changes in pricing regulations for generics
Partnerships with healthcare providers for contract manufacturing
Regulatory changes impacting drug pricing and approvals
Technological disruptions in drug manufacturing processes
Intensifying competition from local and international generic manufacturers
Potential entry of large pharmaceutical companies into the generic market
Low liquidity risk due to a high current ratio
Minimal financial risk from low debt levels
moderate - The company's performance is somewhat linked to GDP growth, as increased consumer spending can drive demand for pharmaceuticals.
Low - Bliss GVS Pharma has minimal debt, reducing sensitivity to interest rate fluctuations. However, higher rates could indirectly affect consumer spending on healthcare.
minimal - The company operates with a low debt-to-equity ratio, indicating limited reliance on credit markets.
growth - Investors are likely attracted to Bliss GVS Pharma due to its strong revenue growth and expanding market presence.
moderate - The stock has shown high returns recently, but its performance may be subject to market fluctuations.
